Home » Market News » DirectorsTalk Highlights » Avacta Group “promising evaluation of the Affimer reagents in Integumen’s sensor systems”
Avacta Group Plc

Avacta Group “promising evaluation of the Affimer reagents in Integumen’s sensor systems”

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has noted the update by Integumen plc (LON:SKIN) provided today regarding their ongoing development of Affimer-based sensors for the coronavirus in waste water and in human breath.

 Dr Alastair Smith, Chief Executive of Avacta Group commented:

“I am very pleased to learn of the promising evaluation of the Affimer reagents in Integumen’s sensor systems. Once detailed validation of the sensors has been carried out using SARS-COV-2 virus samples at the University of Aberdeen, and we have reviewed those data, Avacta will provide a further update to the market.” 

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.